Reading CCLD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCLD free→Reading CCLD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCLD free→
NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. The company is unprofitable over the past year, so its earnings quality can't be assessed, and risk is high. Peer multiples imply a price about 44% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. Key factors to watch include guidance changes and sector trends, as these could significantly impact the stock's trajectory. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $2.24. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.24 CCLD trades at 8× p/e, below its 15× p/e peer median. Our $4.02 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 44% below a flat-multiple fair value, below our forecast of about 3%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -26.53x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.09 → $0.06 (-32.2% / 30d). 0 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 67% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$271.
How much price usually moves either way.
On a bad day, this stock has moved -$560.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,505.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Meeting this EBITDA target shows good performance. It can bring in more investors.
Confirms:Adjusted EBITDA reported at or above $29M in Q3 2026.
Disproves:Adjusted EBITDA was below $29M in Q3 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CCLD yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 4, 2026, at the Annual Meeting of Shareholders (the “Annual Meeting”) of CareCloud, Inc., (the “Company”), held in Somerset, New Jersey, the Company’s shareholders approved the 2026 Equity Incentive Plan (the “Plan”) to authorize the issuance of up to 1,000,000 shares of the Company’s common stock. The Company’s Board of Directors previousl…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CCLD CareCloud Inc | Above typical Show detailsSector percentile: 76 of 100 | inexpensive | high |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 78 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to increase EPS by 100-130% in 2026 compared to 2025.
Stated in 2 of last 2 quarters. EPS guidance of $0.20–$0.23 for 2026 represents a 100-130% increase from the $0.10 achieved in 2025. The trajectory is on track with management's stated priority.
“EPS guidance of $0.20–$0.23 represents a 100-130% increase from the $0.10 achieved in full year 2025.”
“We are targeting an EPS increase of 100-130% in 2026.”
Management reaffirms its 2026 revenue guidance of $128M to $132M.
Stated in 2 of last 2 quarters. Revenue guidance for 2026 is reaffirmed at $128M to $132M. Revenue in 2026-Q1 was $31.27M, indicating mixed progress towards the annual target.
“We are reaffirming our 2026 guidance based on our confidence for the year.”
“We remain confident in our 2026 revenue guidance.”
Management targets adjusted EBITDA of $29–$31M for the fiscal year 2026.
Stated in 2 of last 2 quarters. Adjusted EBITDA guidance for 2026 is set at $29–$31M, up from $27.5M in 2025. The financials indicate a stable trajectory towards this target.
“Adjusted EBITDA guidance is $29–$31 million compared to the 2025 amount of $27.5 million.”
Why it matters: Reaffirming revenue guidance shows confidence in growth. It can boost investor trust.
Confirms:Management says the 2026 revenue guidance will stay the same in the next call.
Disproves:Management lowers 2026 revenue guidance in the next earnings call.
Why it matters: Changes in leadership can affect strategy and performance. This may change investor confidence.
Confirms one read:Appointment of a new executive with a strong track record in healthcare.
Confirms the other:More key executives might leave. There are no clear replacements.
Why it matters: Achieving this EPS growth shows strong profitability. It can improve market perception.
Confirms:EPS growth reported at 100% or more in Q3 2026.
Disproves:EPS growth reported below 100% in Q3 2026.
above of this Current Report on Form 8-K is incorporated by reference herein. On May 15, 2026 (the “Redemption Date”), the Company completed the full Redemption of all issued and outstanding shares of its Series B Preferred Stock, in accordance with the terms of the Certificate of Designation governing the Series B Preferred Stock, as previously filed with the Delaware Secretary of State. The Redemption Price paid to each holder of record of the Series B Preferred Stock was $27.52 per share (…
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. Credit Agreement On April 13, 2026, CareCloud, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A., as administrative agent, issuing bank and a lender (“Citizens”), Provident Bank, as a lender (“Provident”), and the other parties thereto, which provides for a $40.0 million term loan facility and a $10.0 million revolving credit facility (collectively, the “Credit Facility”). The term loan facility a…
The Warrant and the shares issuable upon exercise thereof will be issued in reliance on the applicable exemption from registration under the Securities Act of 1933, as amended.
“We are targeting adjusted EBITDA of $29–$31M in 2026.”